Preisser, Felix; Incesu, Reha-Baris; Rajwa, Pawel; Chlosta, Marcin; Nohe, Florian; Ahmed, Mohamed; Abreu, Andre Luis; Cacciamani, Giovanni; Ribeiro, Luis; Kretschmer, Alexander;
...
BACKGROUND AND OBJECTIVE: Persistent prostatic specific antigen (PSA) represents a poor prognostic factor for recurrence after radical prostatectomy (RP). However, the impact of persistent PSA on oncologic outcomes in patients undergoing salvage RP is unknown. To investigate the impact of persistent PSA after salvage RP on long-term oncologic outco...
Serafim, Cindy; Ramos, Miguel A.; Yilmaz, Tugce; Sousa, Nadine R.; Yu, Kang; Van Geel, Maarten; Ceulemans, Tobias; Saudreau, Marc; Somers, Ben; 50928; Ameglio, Thierry;
...
status: published
Kwong, Fong Lien Audrey; Kristunas, Caroline; Davenport, Clare; Deeks, Jon; Mallett, Sue; Agarwal, Ridhi; Kehoe, Sean; Timmerman, Dirk; 17301; Bourne, Tom; 56124; Stobart, Hilary;
...
OBJECTIVE: Symptom-triggered testing for ovarian cancer was introduced to the UK whereby symptomatic women undergo an ultrasound scan and serum CA125, and are referred to hospital within 2 weeks if these are abnormal. The potential value of symptom-triggered testing in the detection of early-stage disease or low tumor burden remains unclear in wome...
Obermayr, Eva; Mohr, Thomas; Schuster, Eva; Braicu, Elena Ioana; Taube, Eliane; Sehouli, Jalid; Vergote, Ignace; 2443; Pujade-Lauraine, Eric; Ray-Coquard, Isabelle; Harter, Philipp;
...
Disease progression is a major problem in ovarian cancer. There are very few treatment options for patients with platinum-resistant ovarian cancer (PROC), and therefore, these patients have a particularly poor prognosis. The aim of the present study was to identify markers for monitoring the response of 123 PROC patients enrolled in the Phase I/II ...
Lal, S.; Paine, P.; Tack, J.; 15849; Aziz, Q.; Barazzoni, R.; Cuerda, C.; Jeppesen, P.; Joly, F.; Lamprecht, G.; Mundi, M.;
...
The role of long-term parenteral support in patients with underlying benign conditions who do not have intestinal failure (IF) is contentious, not least since there are clear benefits in utilising the oral or enteral route for nutritional support. Furthermore, the risks of long-term home parenteral nutrition (HPN) are significant, with significant ...
Hasegawa, Kosei; Takahashi, Shunji; Ushijima, Kimio; Okadome, Masao; Yonemori, Kan; Yokota, Harushige; Vergote, Ignace; 2443; Monk, Bradley J.; Tewari, Krishnansu S.; Fujiwara, Keiichi;
...
BACKGROUND: In the phase 3 EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 study, cemiplimab significantly improved overall survival (OS) versus chemotherapy for patients with recurrent or metastatic cervical cancer who progressed after first-line platinum-based chemotherapy. We present a post hoc subgroup analysis of patients enrolled in Japan. METHODS: Pat...
Jahnke, Kevin; Struve, Nina; Hofmann, Daniel; Gote, Martin Julius; 141520; Bach, Margund; Kriegs, Malte; Hausmann, Michael;
status: published
Wei, Fang-Fei; Mariottoni, Beatrice; An, De-Wei; Pellicori, Pierpaolo; Yu, Yu-Ling; Verdonschot, Job A.J.; Liu, Chen; Ahmed, Fozia Z.; Petutschnigg, Johannes; Rossignol, Patrick;
...
AIMS: Few randomized trials assessed the changes over time in the chronotropic heart rate (HR) reactivity (CHR), HR recovery (HRR) and exercise endurance (EE) in response to the incremental shuttle walk test (ISWT). We addressed this issue by analysing the open HOMAGE (Heart OMics in Aging) trial. METHODS: In HOMAGE, 527 patients prone to heart fai...
Feenstra, Lian; Reijrink, Melanie; Pasch, Andreas; Smith, Edward R.; Visser, Lotte M.; Bulthuis, Marian; Lodewijk, Monique E.; Mastik, Mirjam F.; Greuter, Marcel J.W.; Slart, Riemer H.J.A.;
...
AIMS: Calciprotein particles (CPPs) are circulating calcium and phosphate nanoparticles associated with development of vascular calcification (VC) in chronic kidney disease (CKD). Although recent studies have been focusing on associations of CPPs with presence of VC in CKD, insights in the underlying processes and mechanisms by which CPPs might agg...
Collinson, Fiona Royle, Kara-Louise Swain, Jayne Ralph, Christy Maraveyas, Anthony Eisen, Tim Nathan, Paul Jones, Robert Meads, David Min Wah, Tze
...
Published in
Health technology assessment (Winchester, England)
Treatment breaks in cancer are of significant interest to patients and health professionals. Renal cell carcinoma is the most common type of kidney cancer. Sunitinib and pazopanib are both targeted treatments. They were commonly used to treat advanced kidney cancer but often cause side effects, sometimes requiring use of a reduced dose or even stop...